Skip to main content
. Author manuscript; available in PMC: 2014 Jan 2.
Published in final edited form as: Inflamm Bowel Dis. 2011 Sep 26;18(5):10.1002/ibd.21867. doi: 10.1002/ibd.21867

Figure 1.

Figure 1

Imiquimod induces the expression of type I IFN in the gastrointestinal (GI) tract. Oral administration of Imiquimod (30 mg/kg body wt) to Balb/c mice exhibited differential induction in the expression of type I IFN (α, β) in various parts of the GI tract. In the stomach, no significant changes in the expression type I IFN were noted. In the jejunum, Imiquimod treatments led to significant increases in IFN-α2 and IFN-β expression at the 2 hours time point. In the proximal & distal colon treatments led to significant increases in both IFN-α2 and IFN-β expression at 6 &18 hours time points. Similar type I IFN induction was observed in spleen. N = 5; results represent the data from three individual experiments and expressed as the mean ± SEM (* P < .05; ** P < .01).